Card image cap

Icon Oncology Conference postponed to 3 – 5 June 2022

In light of the current trend and projected peak time of the COVID-19 pandemic in South Africa, Icon Oncology has concluded that it will not be possible to continue with plans of hosting the Icon 2020 Conference conference in October 2020. The Icon 2020 Conference organising ...
Card image cap

Patient care and staff well-being in oncology during the coronavirus pandemic – ethical considerations

An editorial on patient care and staff well-being during the corona virus pandemic has been published in the SA Journal of Oncology by Prof Raymond Abratt who is the Head of Clinical Governance at Icon Oncology. Icon Oncology continues to provide treatment and support to cancer ...
Card image cap

ASCO Guidelines to Improve Clinician Communication with Patients

Clear and effective communication is a core element of patient-centered oncology care.Oncology is a challenging field with high stakes and vulnerable patients. The treatment regimens used are often highly complex and may be toxic even at therapeutic doses. Oncology care is a multidisciplinary speciality. ...
Card image cap

TAILORx trial results – further clarity on the utility of the 21-gene assay in early breast cancer

The results of the TAILORx trial that were presented at the recent ASCO meeting and published in the NEJM in June will further assist in the clinical decision-making around adjuvant therapy in early breast cancer patients. (1) The uncertainty about the best treatment approach for women ...
Card image cap

Chemotherapy-Induced Nausea and Vomiting (CINV) – Guideline adherence for Low and Minimal Emetogenic Regimens

ICON supports appropriate and adequate anti-emesis for all patients receiving chemotherapy. This is crucial to improving quality of life during chemotherapy treatment and has an impact on patient outcomes (1). Modern antiemetic regimens have relegated chemotherapy induced nausea and vomiting (CINV) to a much less feared ...
Card image cap

Cervical Cancer Control in HIV infected woman past, present and future

We know that the incidence of both cervical dysplasia and neoplasia is significantly increased in HIV-infected women, and the prognosis is worse compared with HIV-uninfected women (Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA et al. HIV Infection and Survival Among Women With Cervical Cancer. J ...
Card image cap

The ICON Clinical Team introduces the Royal College of Radiologists Radiotherapy Dose Fractionation 2nd Edition that was published in December 2016

The Faculty of Clinical Oncology of the Royal College of Radiologists published a comprehensive review on evidence-base Radiotherapy Dose Fractionation in December 2016. ...
Card image cap

Breast Cancer: Changes in 8th AJCC TNM Classification

The eighth edition of the TNM classification of AJCC (American Joint Commission of Cancer) (2) was released in May this year. This was the first update since the 7th edition of 2009. The changes from the 7th edition that are of clinical relevance include: ...
Card image cap

ICON Chemotherapy Administration Standards & Guidelines published

Belinda Bailey and David Eedes of Icon were invited to present the ICON Chemotherapy Administration Standards & Guidelines to delegates on the recent SASCRO/SASMO 2017 Conference. They would like to share the slide set and abstract from the prestigious national event with you on the Icon website. ...
Card image cap

PERSEPHONE Trial report from ASCO – Shorter duration adjuvant trastuzumab for HER2+ breast cancer non-inferior and with fewer cardiac side effects

The results of the PERSEPHONE trial, a phase III randomized, multicentre, non-inferiority clinical trial comparing 6 months of adjuvant trastuzumab to the current standard of 12 months, were presented at ASCO in May this year. Over 4,000 women with HER2-positive, early-stage breast cancer were randomised to ...